Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, James V. Cassella, Maria Colavincenzo et al.|Journal of the American Academy of Dermatology|2022Cited by 80
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, James V. Cassella, Matthew Zirwas et al.|Journal of the American Academy of Dermatology|2024Cited by 79